NewsRoom Articles

FridayMar 13, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK The company operates at the nexus of targeted cancer biology and combination therapy innovation These partnerships help underscore LIXTE’s broader strategy: enhancing established cancer treatments through its first-in-class compound LB 100 LIXTE Biotechnology Holdings (NASDAQ: LIXT) continues to promote its lead oncology asset, LB 100, through a partnership-driven model designed to accelerate development and improve scientific validation. Recently, the company announced the expansion of its ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center and GSK plc to evaluate LB 100…

WednesdayMar 11, 2026 10:00 am

Researchers Trace Differing Pediatric Brain Tumors to Common Source

New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path toward therapies capable of targeting all three at once. The discovery grew out of a deep dive into one of the rarest childhood tumors on record and ended up revealing far more than anyone initially set out to find. Pineoblastoma originates in the pineal gland, a small structure at the brain's core responsible for producing hormones, including melatonin. Cases are rare enough that most specialized pediatric oncology programs handle only a small number each year. Pooling resources across three institutions, St. Jude Children's Research…

MondayMar 09, 2026 3:24 pm

Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy

LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy. Specifically,…

MondayMar 09, 2026 10:00 am

Ongoing Digital Monitoring Could Make Immunotherapy More Accessible

Ongoing digital monitoring could be about to solve one of modern medicine's most frustrating access problems. Life-extending cancer immunotherapies exist and there are numerous patients who could benefit from such therapies, but a mandatory hospital stay requirement currently makes access to immunotherapy nigh impossible for rural and underserved patients. However, a growing body of evidence now suggests that continuous remote monitoring could remove the need for hospital stays post immunotherapy. CAR-T cell therapies and related immunotherapies have reshaped what is possible for patients with certain blood cancers, producing remission rates that were unthinkable a generation ago. Thirteen of these treatments now carry FDA approval across two therapy categories. Getting them to patients,…

MondayMar 09, 2026 9:00 am

Frontieras North America Inc. Is ‘One to Watch’

Frontieras’ patent portfolio includes protection across five continents and nine countries, covering approximately 85% of global coal production. The FASForm(TM) process is designed as a closed-loop, zero-waste system that converts coal into multiple market-ready energy and industrial products. Long-term feedstock and product offtake frameworks are in place for the company’s flagship commercial facility. The Mason County project is structured as a large-scale infrastructure development with established engineering, construction, operations, logistics, and insurance partners. Frontieras’ commercialization strategy focuses on replicable facilities serving established energy and chemicals markets with existing demand. Frontieras North America is an energy and environmental technology company focused…

FridayMar 06, 2026 11:15 am

GridAI Technologies Corp. (NASDAQ: GRDX) Is Capitalizing on the Data Center and AI-Driven Transformation of the Energy Sector

AI data centers are rapidly increasing electricity consumption, creating new and significant pressures on America’s power infrastructure, with analysts warning that reliable electricity supply could become a defining constraint in global AI competition. Large AI facilities require integrated control of multiple energy assets and market inputs, with real-time monitoring and analytics becoming essential to the management of complex energy systems supporting AI infrastructure. GridAI is developing software to coordinate grid power, on-site generation, battery storage and backup systems for AI data-center campuses. Artificial intelligence has triggered a global race for computing capacity, but a serious bottleneck is beginning to emerge:…

FridayMar 06, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents The company is advancing LB-100 through clinical development in collaboration with academic and research institutions Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to…

WednesdayMar 04, 2026 11:29 am

TinyGemsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Identifies Amp Z as Stealth Hyperscale AI Data Center Partner

GridAI Technologies (NASDAQ: GRDX) announced that Amp Z has been identified as the previously disclosed stealth-mode hyperscale artificial intelligence data center developer referenced in the Company’s November 2025 Letter of Intent announcement. Under the LOI, GridAI is expected to serve as the energy orchestration and optimization platform across Amp Z’s planned 5GW-plus portfolio of AI data center campuses in North America over the next five to 10 years. GridAI’s platform is designed to coordinate onsite and grid-connected energy resources, including battery storage, distributed generation and renewable integration, into a unified operating system that supports speed-to-power, reliability and cost optimization. The collaboration is structured to generate recurring operating revenue tied to long-term campus…

WednesdayMar 04, 2026 9:00 am

Reports Indicate US Military Used Anthropic’s AI in Iran Strikes

Reports indicate the U.S. military wasstill running Anthropic's AI models during strikes on Iran even after President Trump had formally ordered all federal agencies to stop using models developed by Anthropic. Axios and the Wall Street Journal both flagged the contradiction, and it immediately raised a pointed question about whether advanced artificial intelligence models can realistically be pulled from active operations once they have been built into the infrastructure of modern warfare. Journalists at both outlets reported that commanders relied on the technology throughout the large joint assault with Israel launched on Saturday. The Wall Street Journal reports that it…

MondayMar 02, 2026 10:00 am

New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer

A new study may have just given brain surgeons a significantly better way to fight cancer without compromising how patients live afterward. Published in Science Advances, the research unlocks a layer of information already sitting in the operating room, one that surgeons have never had the tools to interpret until now. Awake brain mapping has anchored neurosurgical practice for generations. The procedure keeps patients conscious while surgeons deliver precise electrical pulses to targeted brain regions, monitoring responses to verbal tasks as they operate. Accurate, timely answers indicate a region is safe to remove, while hesitation or speech failure signals the opposite, and because the brain carries no pain-sensing nerves, patients feel none of…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000